Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Table 1

Demographics and baseline patient characteristics.

Patient number	Age (yr)	Gender	Race	BSA (m^2)	PAH etiology	PAH medications	Duration of illness at transition (yr)	Group
1	46	Female	Chinese	1.63	CTD associated PAH	Sildenafil	1.0	Bosentan
2	64	Male	Chinese	1.79	CTD associated PAH	Sildenafil	0.7	Bosentan
3	44	Female	Chinese	1.50	HPAH	None	0	Bosentan
4	29	Male	Chinese	1.55	HPAH	None	0	Bosentan
5	64	Female	Chinese	1.70	CTD associated PAH	Sildenafil	2.3	Bosentan
6	58	Female	Chinese	1.55	IPAH	Sildenafil	2.2	Bosentan
7	45	Female	Chinese	1.55	CTD associated PAH	Sildenafil	0	Bosentan
8	59	Female	Chinese	1.50	IPAH	Sildenafil	0	Bosentan
9	54	Female	Chinese	1.44	IPAH	None	2.8	Ambrisentan
10	57	Female	Chinese	1.46	CTD associated PAH	None	0	Ambrisentan
11	30	Female	Chinese	1.53	CTD associated PAH	None	0	Ambrisentan
12	33	Female	Chinese	1.48	IPAH	Sildenafil	0.2	Ambrisentan
13	72	Male	Chinese	1.66	IPAH	None	0	Ambrisentan
14	18	Male	Chinese	1.59	CHD associated PAH, repaired	Sildenafil	0	Ambrisentan
15	18	Female	Chinese	1.45	CHD associated PAH, repaired	None	0	Ambrisentan
16	35	Female	Chinese	1.59	CHD associated PAH, repaired	None	0	Ambrisentan
17	33	Female	Chinese	1.53	CHD associated PAH, repaired	None	0	Ambrisentan
18	22	Female	Chinese	1.39	IPAH	None	0	Ambrisentan
19	40	Female	Chinese	1.46	IPAH	None	0	Ambrisentan
20	59	Female	Chinese	1.50	IPAH	Sildenafil	0	Ambrisentan

PAH, pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; CTD, collagen tissue disease; CHD, congenital heart disease; BSA, body surface area.